Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old-Reference-Cited by-同舟云学术

Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old

Published:2016-10-29 Issue:2 Volume:35 Page:242-246
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Bigot Frederic,Boudou-Rouquette Pascaline,Arrondeau Jennifer,Thomas-Schoemann Audrey,Tlemsani Camille,Chapron Jeanne,Huillard Olivier,Cessot Anatole,Vidal Michel,Alexandre Jerome,Blanchet Benoit,Goldwasser Francois

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-016-0400-5.pdf

Reference18 articles.

1. Zeng C, Wen W, Morgans AK, Pao W, Shu X-O, Zheng W (2015) Disparities by race, age, and sex in the improvement of survival for major cancers: results from the national cancer institute surveillance, epidemiology, and end results (SEER) program in United States, 1990 to 2010. JAMA Oncol 1(1):88–96

2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L (2005) Erlotinib in previously treated non–small-cell lung cancer. N. Engl J Med 353(2):123–132

3. Chen Y-M, Lai C-H, Rau K-M, Huang C-H, Chang H-C, Chao T-Y, Tseng C-C, Fang W-F, Chen Y-C, Chung Y-H, Wang Y-H, Su M-C, Huang K-T, Liu S-F, Chen H-C, Chang Y-C, Chang Y-P, Wang C-C, Lin M-C Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer 98:99–105

4. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA (2008) Erlotinib for advanced non–small-cell lung cancer in the elderly: an analysis of the national cancer institute of canada clinical trials group study BR.21. J. Clin. Oncol. 26(14):2350–2357

5. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA (2007) Phase II clinical trial of chemotherapy-Naïve patients ≥70 Years of age treated with erlotinib for advanced non–small-cell lung cancer. J. Clin Oncol 25(7):760–766

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Search of the Perfect Thrombosis and Bleeding-Associated Cancer Scale;Seminars in Thrombosis and Hemostasis;2023-10-18

2. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report;Journal of Geriatric Oncology;2022-11

3. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer;Pharmaceutics;2022-09-01

4. Dermatologic adverse events associated with epidermal growth factor receptor inhibitors: current concepts of interdisciplinary problem;Head and Neck Tumors (HNT);2022-02-14

5. Effects of tyrosine kinase inhibitors on androgen, estrogen α, glucocorticoid and thyroid receptors;Toxicology and Applied Pharmacology;2022-01